MIR885 (MicroRNA 885)

Future research must bridge mechanistic insights with clinical innovation. By harmonizing pathophysiological understanding with precision medicine approaches, this synthesis underscores the potential to transform SIMD management from supportive care to targeted functional recovery.

Our findings highlight a distinct circulating miRNA signature associated with advanced pancreatic cancer, supporting the potential role of hsa-miR-100-5p, hsa-miR-122-5p, hsa-miR-885-5p, hsa-miR-34a-5p, and hsa-miR-193a-5p as minimally invasive biomarkers for disease detection and staging. Larger, multicenter studies including early-stage patients and disease control groups will be required to validate these biomarkers and determine their clinical utility.

Of the ten putative diagnostic biomarkers, extracellular vesicle-associated miR-21-3p, miR-26a-5p, miR-130a-3p, miR-139 and miR-219a-5p are the most promising as their expression in extracellular vesicle preparations appears to reflect that in endometrial tissue. However, there are significant concerns regarding study quality, limited adherence to consensus recommendations on extracellular vesicle research and lack of evidence supporting biomarkers being encapsulated within extracellular vesicles.

In addition, qRT-PCR and clinical correlation analyses revealed that circ_IGF2BP1, miR-885-3p, and TK1 are closely associated with clinical diagnosis, prognosis, and treatment in LUAD patients. Collectively, these findings indicate that circ_IGF2BP1 modulates malignant phenotypes and cisplatin resistance in LUAD via the miR-885-3p/TK1 axis by regulating DNA damage and apoptosis pathways.

miR‑885‑5p overexpression sensitized liver cancer cells to the CDK4/6 inhibitors palbociclib, ribociclib and abemaciclib. The present findings collectively demonstrated that miR‑885‑5p induces cell cycle arrest and enhances CDK4/6 inhibitor sensitivity in liver cancer, suggesting its potential as a therapeutic target.

Our study identified a distinct circulating miRNA signature of six miRNAs that reliably differentiates NF1 patients from non-affected individuals. These miRNAs are implicated in regulating NF1 downstream pathways and signaling processes involved in tumorigenesis.

This study suggests that the specific expression of miRNA-1296-5p, miR-499a-5p, miR-374a-5p and miR-370-3p in the serum exosomes of LC, which has diagnostic potential. And the combination of miRNA-1296-5p, miR-499a-5p and miR-370-3p with CEA can further enhance this potential.

Utility as prognostic biomarkers was confirmed in univariate and multivariate analysis for CA19-9, CRP, and NLR. The selected miRNAs and LAR were not confirmed as reliable prognostic markers in PC.

PKS + E. By inhibiting exosomal miR-885-5p, coli is linked to CRC metastases, offering a possible target for therapeutic intervention.

The dysregulated miRNAs identified in PC may regulate KRAS and some are associated with clinically relevant features, highlighting their potential as biomarkers and therapeutic targets in PC treatment. However, experimental validation is required for confirmation.

Although preoperative TAE does not seem to impact CTC shedding, CTC clearance may prove to be a valuable biomarker in prognosticating HCC. A larger study to evaluate the significance of CTCs as a prognostic marker is warranted to further evaluate these findings.